Cited by 463Acute Myeloid Leukemia ResearchCancer-related Molecular PathwaysRetinoids in leukemia and cellular processes

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression

Jädersten, Martin, Saft, Leonie, Smith, Alexander, Kulasekararaj, Austin, Pomplun, Sabine, Göhring, Gudrun, Hedlund, Anette, Hast, Robert, Schlegelberger, Brigitte, Porwit, Anna, Hellström-Lindberg, Eva, Mufti, Ghulam J.·2011·Journal of Clinical Oncology

DOI 10.1200/jco.2010.31.8576

Open this paper in CoChat — free account

Abstract

Purpose: To determine the frequency of TP53 mutations and the level of p53 protein expression by immunohistochemistry (IHC) in low-risk myelodysplastic syndromes (MDS) with del(5q) and to assess their impact on disease progression. Patients and Methods: Pre- and postprogression bone marrow (BM) samples from 55 consecutive patients with International Prognostic Scoring System low risk (n = 32) or intermediate-1 risk (n = 23) were studied by next-generation sequencing of TP53. IHC for p53 was performed on 148 sequential BM samples. Results: TP53 mutations with a median clone size of 11% (range, 1% to 54%) were detected in 10 patients (18%) already at an early phase of the disease. Mutations were equally common in low-risk and intermediate-1–risk patients and were associated with evolution to acute myeloid leukemia (5 of 10 v 7 of 45; P = .045). Nine of 10 patients carrying mutations showed more than 2% BM progenitors with strong p53 staining. The probability of a complete cytogenetic response to lenalidomide was lower in mutated patients (0 of 7 v 12 of 24; P = .024). Conclusion: By using sensitive deep-sequencing technology, we demonstrated that TP53 mutated populations may occur at an early disease stage in almost a fifth of low-risk MDS patients with del(5q). Importantly, mutations were present years before disease progression and were associated with an increased risk of leukemic evolution. TP53 mutations could not be predicted by common clinical features but were associated with p53 overexpression. Our findings indicate a previously unrecognized heterogeneity of the disease which may significantly affect clinical decision making.

Integrity signals

Registry

Crossref · 10.1200/jco.2010.31.8576

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Self-citation
Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes
Malcovati, L., Germing, U., Kuendgen, A., Porta, M. G. D., Pascutto, C., Invernizzi, R., Giagounidis, A. A. N., Hildebrandt, B., BERNASCONI, P. P., Knipp, S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5696 · Cited by 1,029
p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies
Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P., & Fenaux, P. (1994) · Blood · doi:10.1182/blood.v84.9.3148.3148 · Cited by 592
A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q– syndrome
Barlow, J. L., Drynan, L. F., Hewett, D. R., Holmes, L. R., Lorenzo-Abalde, S., Lane, A. L., Jolin, H. E., Pannell, R., Middleton, A. J., Wong, S. H., et al. (2009) · Nature Medicine · doi:10.1038/nm.2063 · Cited by 349
Mutations With Loss of Heterozygosity of p53 Are Common in Therapy-Related Myelodysplasia and Acute Myeloid Leukemia After Exposure to Alkylating Agents and Significantly Associated With Deletion or Loss of 5q, a Complex Karyotype, and a Poor Prognosis
Christiansen, D. H., Andersen, M. K., & Pedersen-Bjergaard, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1405 · Cited by 308
RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up
Padua, R. A., Guinn, B., Al-Sabah, A., Smith, M. T., Taylor, C., Pettersson, T., Ridge, S. A., Carter, G., White, D., Oscier, D. G., et al. (1998) · Leukemia · doi:10.1038/sj.leu.2401044 · Cited by 213
Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31
Giagounidis, A. A. N., Germing, U., Haase, S. P., Hildebrandt, B., Schlegelberger, B., Schoch, C., Wilkens, L., Heinsch, M., Willems, H. P. J., Aivado, M. A., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403189 · Cited by 210
Self-citation
Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations.
Laï, J., Preudhomme, C., Zandecki, M., FLACTIF, M., Vanrumbeke, M., Lepelley, P., Wattel, E., & Fenaux, P. (1995) · PubMed · Cited by 197
Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS- derived leukemia
Sugimoto, K., Hirano, N., Toyoshima, H., Chiba, S., Mano, H., Takaku, F., Yazaki, Y., & Hirai, H. (1993) · Blood · doi:10.1182/blood.v81.11.3022.3022 · Cited by 123

Flagged first, then by citations

Show all 33 references

Research works printed but not linked: 9

Preudhomme C, 1994, Leukemia, 8, 2241
Lai JL, 1995, Leukemia, 9, 370
Kitagawa M, 1994, Am J Pathol, 145, 338
Ludwig L, 1992, Leukemia, 6, 1302
Fidler C, 2004, Haematologica, 89, 865
Fenaux P, 1990, Nouv Rev Fr Hematol, 32, 341
Lepelley P, 1994, Leukemia, 8, 1342
Ramos F, 2002, Haematologica, 87, 381
Orazi A, 1996, Mod Pathol, 9, 48

Sorted by citations

Items 101–200 of 462

Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes
Meggendorfer, M., Haferlach, C., Kern, W., & Haferlach, T. (2017) · Haematologica · doi:10.3324/haematol.2017.166173 · Cited by 54
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities
Möllgård, L., Saft, L., Treppendahl, M. B., Dybedal, I., Nørgaard, J. M., Astermark, J., Ejerblad, E., Garelius, H. G., Dufva, I. H., Jansson, M., et al. (2011) · Haematologica · doi:10.3324/haematol.2010.039669 · Cited by 51
Self-citation
TP 53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis
Loghavi, S., Al‐Ibraheemi, A., Zuo, Z., Garcia‐Manero, G., Yabe, M., Wang, S. A., Kantarjian, H. M., Yin, C. C., Miranda, R. N., Luthra, R., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13529 · Cited by 52
Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications
Stahl, M. F., & Zeidan, A. M. (2017) · Cancer · doi:10.1002/cncr.30585 · Cited by 52
p53 functional deficiency in human colon cancer cells promotes fibroblast-mediated angiogenesis and tumor growth
Hayashi, Y., Tsujii, M., Kodama, T., Akasaka, T., Kondo, J., Hikita, H., Inoue, T., Tsujii, Y., Maekawa, A., Yoshii, S., et al. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw085 · Cited by 51
The biology and clinical impact of genetic lesions in myeloid malignancies
Lindsley, R. C., & Ebert, B. L. (2013) · Blood · doi:10.1182/blood-2013-06-460295 · Cited by 50
High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome
Cleven, A. H. G., Nardi, V., Ok, C. Y., Goswami, M., Cin, P. D., Zheng, Z., Iafrate, A. J., Hamid, M. A. A., Wang, S. A., & Hasserjian, R. P. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.153 · Cited by 50
The molecular mechanism of thalidomide analogs in hematologic malignancies
Lindner, S., & Krönke, J. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1450-z · Cited by 51
A decade of progress in myelodysplastic syndrome with chromosome 5q deletion
List, A., Ebert, B. L., & Fenaux, P. (2018) · Leukemia · doi:10.1038/s41375-018-0029-9 · Cited by 49
Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis
Ramos, F., Spanish Group for Myelodysplastic Syndromes (GESMD), Robledo, C., Izquierdo-García, F. M., Suárez‐Vilela, D., Benito, R., Fuertes, M., Insunza, A., Barragán, E., Rey, M. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9026 · Cited by 49
Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations
Scharenberg, C., Giai, V., Pellagatti, A., Saft, L., Dimitriou, M., Jansson, M., Jädersten, M., Grandien, A., Douagi, I., Neuberg, D. S., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.152025 · Cited by 47
Self-citation
The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes
Zhang, L., Padron, E., & Lancet, J. E. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.10.006 · Cited by 47
Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes
Kulasekararaj, A. G., Mohamedali, A. M., & Mufti, G. J. (2013) · British Journal of Haematology · doi:10.1111/bjh.12435 · Cited by 47
Self-citation
Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes
Giagounidis, A. A. N., Mufti, G. J., Fenaux, P., Germing, U., List, A. F., & MacBeth, K. J. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1863-5 · Cited by 46
Self-citation
Recurrent genetic defects on chromosome 5q in myeloid neoplasms
Hosono, N., Makishima, H., Mahfouz, R. Z., Przychodzen, B. P., Yoshida, K., Jerez, A., LaFramboise, T., Polprasert, C., Clemente, M. J., Shiraishi, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14130 · Cited by 45
Prognostic scoring systems for myelodysplastic syndromes ( MDS ) in a population‐based setting: a report from the Swedish MDS register
Berggren, D. M., Folkvaljon, Y., Engvall, M., Sundberg, J., Lambe, M. P., Antunović, P., Garelius, H. G., Lorenz, F., Nilsson, L., Rasmussen, B. E. H., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15243 · Cited by 47
Self-citation
Mechanisms of lenalidomide sensitivity and resistance
Martínez-Høyer, S., & Karsan, A. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.09.196 · Cited by 48
Recent insights into inherited bone marrow failure syndromes
Parikh, S. P., & Bessler, M. (2012) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32834eca77 · Cited by 44
Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts
MAASSEN, A. P., Strupp, C., Giagounidis, A. A. N., Kuendgen, A., Nachtkamp, K., Hildebrandt, B., Gattermann, N., Aul, C., Haas, R. R., & Germing, U. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.09.021 · Cited by 46
Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond
Talati, C., Sallman, D. A., & List, A. F. (2017) · Seminars in Hematology · doi:10.1053/j.seminhematol.2017.06.003 · Cited by 45
Morphology, cytogenetics and classification of MDS
Giagounidis, A. A. N., & Haase, D. T. (2013) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2013.09.004 · Cited by 44
Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer
Teo, M. T. W., Dyrskjøt, L., Nsengimana, J., von Buchwald, C., Snowden, H. H., Morgan, J., Jensen, J. B., Knowles, M. A., Taylor, G. R., Barrett, J. H., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu014 · Cited by 43
Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome
Martinez-Høyer, S., Deng, Y., Parker, J., Jiang, J., Mo, A., Docking, T. R., Gharaee, N., Li, J., Umlandt, P., Fuller, M., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0497-9 · Cited by 42
Self-citation
Developing a classification of hematologic neoplasms in the era of precision medicine
Cazzola, M., & Sehn, L. H. (2022) · Blood · doi:10.1182/blood.2022015849 · Cited by 43
Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide
Negoro, E., Radivoyevitch, T., Polprasert, C., Ademà, V., Hosono, N., Makishima, H., Przychodzen, B. P., Hirsch, C., Clemente, M. J., Nazha, A., et al. (2016) · Leukemia · doi:10.1038/leu.2016.228 · Cited by 43
Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia
Palomo, L., Ibáñez, M., Abáigar, M., Vázquez, I., Álvarez, S., Cabezón, M., Tazón‐Vega, B., Rapado, I., Fuster‐Tormo, F., Cervera, J., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16175 · Cited by 44
The functional mechanisms of mutations in myelodysplastic syndrome
Nagata, Y., & Maciejewski, J. P. (2019) · Leukemia · doi:10.1038/s41375-019-0617-3 · Cited by 42
The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions
Lee, E.-J., Podoltsev, N. A., Gore, S. D., & Zeidan, A. M. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.06.004 · Cited by 42
TP53 ‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management
Shah, M. V., Arber, D. A., & Hiwase, D. (2025) · American Journal of Hematology · doi:10.1002/ajh.27655 · Cited by 43
High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS)
Mohamedali, A. M., Gäken, J. A., Ahmed, M., MALIK, F., Smith, A., Best, S., Mian, S. A., Gaymes, T. J., Ireland, R. M., Kulasekararaj, A. G., et al. (2015) · Leukemia · doi:10.1038/leu.2015.110 · Cited by 42
Self-citation
Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies
Adès, L., Bras, F. L., Sébert, M., Kelaïdi, C., Lamy, T., Dreyfus, F., Éclache, V., Delaunay, J., Bouscary, D., Visanica, S., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.045914 · Cited by 41
The International Consensus Classification of myelodysplastic syndromes and related entities
Hasserjian, R. P., Orazi, A., Órfão, A., Rozman, M., & Wang, S. A. (2022) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-022-03417-1 · Cited by 42
Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia
Bochtler, T., Fröhling, S., & Krämer, A. (2015) · Leukemia · doi:10.1038/leu.2015.32 · Cited by 39
Prognostic models in myelodysplastic syndromes
Bejar, R. L. (2013) · Hematology · doi:10.1182/asheducation-2013.1.504 · Cited by 38
RECENT ADVANCES IN THE 5Q- SYNDROME
Pellagatti, A., & Boultwood, J. (2015) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2015.037 · Cited by 40
TP53 in Myelodysplastic Syndromes: Recent Biological and Clinical Findings
Cumbo, C., Tota, G., Anelli, L., Zagaria, A., Specchia, G., & Albano, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103432 · Cited by 39
The Genetics of Myelodysplastic Syndromes: Clinical Relevance
Chiereghin, C., Travaglino, E., Zampini, M., Saba, E., Saitta, C., Riva, E., Bersanelli, M., & Porta, M. G. D. (2021) · Genes · doi:10.3390/genes12081144 · Cited by 42
Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes
Follo, M. Y., Pellagatti, A., Armstrong, R. N., Ratti, S., Mongiorgi, S., De Fanti, S., Bochicchio, M. T., Russo, D., Gobbi, M., Miglino, M., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0416-x · Cited by 36
Knockdown of HSPA9 induces TP53-dependent apoptosis in human hematopoietic progenitor cells
Liu, T., Krysiak, K., Shirai, C. L., Kim, S. P., Shao, J., Ndonwi, M., & Walter, M. J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170470 · Cited by 36
From clonal hematopoiesis to myeloid leukemia and what happens in between: Will improved understanding lead to new therapeutic and preventive opportunities?
Bewersdorf, J. P., Ardasheva, A., Podoltsev, N. A., Singh, A., Biancon, G., Halene, S., & Zeidan, A. M. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100587 · Cited by 37
TIFAB Regulates USP15-Mediated p53 Signaling during Stressed and Malignant Hematopoiesis
Niederkorn, M., Hueneman, K. M., Choi, K., Varney, M., Romano, L. M., Pujato, M., Greis, K., Inoue, J., Meetei, R. A., & Starczynowski, D. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.093 · Cited by 36
Therapeutic strategies in low and high-risk MDS: What does the future have to offer?
Scalzulli, E., Pepe, S., Colafigli, G., & Breccia, M. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100689 · Cited by 36
Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies
Harada, H., & Harada, Y. (2015) · Cancer Science · doi:10.1111/cas.12614 · Cited by 37
The Multifaceted Nature of Myelodysplastic Syndromes: Clinical, Molecular, and Biological Prognostic Features
Greenberg, P. L. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0105 · Cited by 35
How I use molecular genetic tests to evaluate patients who have or may have myelodysplastic syndromes
Steensma, D. P. (2018) · Blood · doi:10.1182/blood-2018-06-860882 · Cited by 34
Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms
Kanagal‐Shamanna, R., Hodge, J. C., Tucker, T., Shetty, S., Yenamandra, A. K., Dixon‐McIver, A., Bryke, C. R., Huxley, E., Lennon, P. A., Raca, G., et al. (2018) · Cancer Genetics · doi:10.1016/j.cancergen.2018.07.003 · Cited by 34
Stathmin is overexpressed and regulated by mutant p53 in oral squamous cell carcinoma
Ma, H., Jin, S., Ju, W., Fu, Y., Tu, Y., Wang, L., Jiang-Li, Zhang, Z., & Zhong, L. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0575-4 · Cited by 34
Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia
Zavras, P. D., Sinanidis, I., Tsakiroglou, P., & Karantanos, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24055018 · Cited by 33
Role of reactive oxygen species in myelodysplastic syndromes
Jing, Q., Zhou, C., Zhang, J., Zhang, P., Wu, Y., Zhou, J., Tong, X., Li, Y., Du, J., & Wang, Y. (2024) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-024-00570-0 · Cited by 33
Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide
Gaballa, M., & Besa, E. C. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2022-3 · Cited by 34
SOHO State of the Art & Next Questions: Myelodysplastic Syndromes: A New Decade
Volpe, V. O., Garcia‐Manero, G., & Komrokji, R. S. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.07.031 · Cited by 33
Novel therapeutic strategies: hypomethylating agents and beyond
Santini, V. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.65.3806843 · Cited by 34
TP53 Mutation Analysis in Clinical Practice: Lessons From Chronic Lymphocytic Leukemia
Malčíková, J., Pavlová, Š., Kozubík, K. S., & Pospı́šilová, Š. (2014) · Human Mutation · doi:10.1002/humu.22508 · Cited by 33
Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes
Fernández‐Mercado, M., Burns, A., Pellagatti, A., Giagounidis, A. A. N., Germing, U., Agirre, X., Prósper, F., Aul, C., Killick, S. B., Wainscoat, J. S., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.086686 · Cited by 33
Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome
Boultwood, J., Pellagatti, A., & Wainscoat, J. S. (2011) · Advances in Biological Regulation · doi:10.1016/j.advenzreg.2011.09.008 · Cited by 32
Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5)
Schuler, E., Giagounidis, A. A. N., Haase, D. T., Shirneshan, K., Büsche, G., Platzbecker, U., Nolte, F., Götze, K. S. S., Schlenk, R. F., Ganser, A., et al. (2015) · Leukemia · doi:10.1038/leu.2015.340 · Cited by 33
Current treatment algorithm for the management of lower-risk MDS
Giagounidis, A. A. N. (2017) · Hematology · doi:10.1182/asheducation-2017.1.453 · Cited by 32
Stem cell factor SALL4, a potential prognostic marker for myelodysplastic syndromes
Wang, F., Guo, Y., Chen, Q., Yang, Z., Ning, N., Zhang, Y., Xu, Y.-G., Xu, X., Tong, C., Chai, L., et al. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-73 · Cited by 31
Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion
Montoro, M. J., Palomo, L., Haferlach, C., Acha, P., Chan, O., Navarro, V., Kubota, Y., Schulz, F. I., Meggendorfer, M., Briski, R. E., et al. (2024) · Blood · doi:10.1182/blood.2024023840 · Cited by 31
TIFA and TIFAB: FHA-domain proteins involved in inflammation, hematopoiesis, and disease
Niederkorn, M., Agarwal, P., & Starczynowski, D. T. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.08.010 · Cited by 31
Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond
Guirguis, A. A., & Ebert, B. L. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.10.004 · Cited by 30
Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma
Dimopoulos, K., Munch‐Petersen, H. F., Eskelund, C. W., Sjø, L. D., Ralfkiaer, E. M., Gimsing, P., & Grønbæk, K. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1466290 · Cited by 29
Genetic instability of modified stem cells - a first step towards malignant transformation?
Steinemann, D., Göhring, G., & Schlegelberger, B. (2013) · Europe PMC (PubMed Central) · Cited by 29
Self-citation
Molecular genetics in myelodysplastic syndromes
Haferlach, T. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.08.009 · Cited by 30
Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes
Komrokji, R. S., & List, A. F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv488 · Cited by 30
The AML–MDS interface—leukemic transformation in myelodysplastic syndromes
Porwit‐MacDonald, A., & Saft, L. (2011) · Journal of Hematopathology · doi:10.1007/s12308-011-0088-6 · Cited by 28
Self-citation
Mutational profiling in patients with MDS: Ready for every-day use in the clinic?
Bacher, U., Kohlmann, A., & Haferlach, T. (2014) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2014.11.005 · Cited by 27
The impact of next generation sequencing technologies on haematological research – A review
Black, J. S., Salto‐Tellez, M., Mills, K., & Catherwood, M. A. (2015) · Pathogenesis · doi:10.1016/j.pathog.2015.05.004 · Cited by 27
Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide
Göhring, G., Lange, K., Hofmann, W. A., Nielsen, K. V., Hellström‐Lindberg, E., Roy, L., Morgan, M. A., Kreipe, H., Büsche, G., Giagounidis, A. A. N., et al. (2011) · Leukemia · doi:10.1038/leu.2011.193 · Cited by 27
Self-citation
Molecular and genetic features of myelodysplastic syndromes
Greenberg, P. L. (2011) · International Journal of Laboratory Hematology · doi:10.1111/j.1751-553x.2011.01390.x · Cited by 27
Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide
Sugimoto, Y., Sekeres, M. A., Makishima, H., Traina, F., Visconte, V., Jankowska, A. M., Jerez, A., Szpurka, H., O’Keefe, C. L., Guinta, K. M., et al. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-4 · Cited by 26
Addition of chromosomal microarray and next generation sequencing to FISH and classical cytogenetics enhances genomic profiling of myeloid malignancies
Mukherjee, S., Sathanoori, M., Ma, Z., Andreatta, M. E., Lennon, P. A., Wheeler, S. R., Prescott, J. L., Coldren, C. D., Casey, T. T., Rietz, H., et al. (2017) · Cancer Genetics · doi:10.1016/j.cancergen.2017.07.010 · Cited by 26
Impact of chromosome alterations, genetic mutations and clonal hematopoiesis of indeterminate potential (CHIP) on the classification and risk stratification of MDS
Ganguly, B. B., Banerjee, D., & Agarwal, M. B. (2017) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2017.10.001 · Cited by 26
Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs
Fuchs, O. (2018) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x18666180522073855 · Cited by 26
Combination of Azacitidine and Lenalidomide in Myelodysplastic Syndromes or acute Myeloid Leukemia—a wise Liaison?
Platzbecker, U., & Germing, U. (2013) · Leukemia · doi:10.1038/leu.2013.140 · Cited by 25
PP2A: The Achilles Heal in MDS with 5q Deletion
Sallman, D. A., Sheng, W., & List, A. F. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00264 · Cited by 26
Current state of prognostication and risk stratification in myelodysplastic syndromes
Zeidan, A. M., Gore, S. D., Padron, E., & Komrokji, R. S. (2015) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000110 · Cited by 25
Loss of 5q in myeloid malignancies – A gain in understanding of biological and clinical consequences
Venugopal, S., Mascarenhas, J. O., & Steensma, D. P. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100735 · Cited by 26
British Society for Haematology guidelines for the management of adult myelodysplastic syndromes
Killick, S. B., Ingram, W. A., Culligan, D. J., Enright, H., Kell, J., Payne, E. M., Krishnamurthy, P., Kulasekararaj, A. G., Raghavan, M., Stanworth, S. J., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17612 · Cited by 25
Self-citation
Treatment of myelodysplastic syndrome in the era of next‐generation sequencing
Tobiasson, M., & Kittang, A. O. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12893 · Cited by 26
Unravelling the Epigenome of Myelodysplastic Syndrome: Diagnosis, Prognosis, and Response to Therapy
Bond, D. R., Lee, H. J., & Enjeti, A. K. (2020) · Cancers · doi:10.3390/cancers12113128 · Cited by 26
Update on cytogenetic and molecular changes in myelodysplastic syndromes
Schlegelberger, B., Göhring, G., Thol, F. R., & Heuser, M. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.618235 · Cited by 24
Self-citation
Characterization of TP 53 mutations in low‐grade myelodysplastic syndromes and myelodysplastic syndromes with a non‐complex karyotype
Wang, W., Routbort, M. J., Tang, Z., Ok, C. Y., Patel, K. P., Daver, N. G., Garcia‐Manero, G., Medeiros, L. J., & Wang, S. A. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12971 · Cited by 26
Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q
Heuser, M., Meggendorfer, M., Cruz, M. M. A., Fabisch, J., Klesse, S., Köhler, L., Göhring, G., Ganster, C., Shirneshan, K., Gutermuth, A., et al. (2015) · Leukemia · doi:10.1038/leu.2015.49 · Cited by 24
Self-citation
CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis
Smith, A., Kulasekararaj, A. G., Jiang, J., Mian, S. A., Mohamedali, A. M., Gäken, J. A., Ireland, R. M., Czepulkowski, B. H., Best, S., & Mufti, G. J. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00050-2 · Cited by 24
Self-citation
Targeting TP53 Mutations in Myelodysplastic Syndromes
Hunter, A. M., & Sallman, D. A. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2019.11.004 · Cited by 25
The Genomics of Myelodysplastic Syndromes: Origins of Disease Evolution, Biological Pathways, and Prognostic Implications
Awada, H. K., Thapa, B., & Visconte, V. (2020) · Cells · doi:10.3390/cells9112512 · Cited by 26
Loss of p53 accelerates the complications of myelodysplastic syndrome in a NUP98-HOXD13–driven mouse model
Xu, H., Menéndez, S., Schlegelberger, B., Bae, N., Aplan, P. D., Göhring, G., DeBlasio, T., & Nimer, S. D. (2012) · Blood · doi:10.1182/blood-2012-01-405332 · Cited by 23
Self-citation
The spectrum of genetic mutations in myelodysplastic syndrome: Should we update prognostication?
Cook, M. R., Karp, J. E., & Lai, C. (2021) · eJHaem · doi:10.1002/jha2.317 · Cited by 26
Bone Marrow Conventional Karyotyping and Fluorescence In Situ Hybridization
He, R. L., Wiktor, A. E., Durnick, D. K., Kurtin, P. J., Dyke, D. L. V., Tefferi, A., Patnaik, M. M., Ketterling, R. P., & Hanson, C. A. (2016) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqw077 · Cited by 24
Single-molecule DNA sequencing of acute myeloid leukemia and myelodysplastic syndromes with multiple TP53 alterations
Lodé, L., Ameur, A., Coste, T., Ménard, A., Richebourg, S., Gaillard, J., Bris, Y. L., Béné, M. C., Lavabre‐Bertrand, T., & Soussi, T. (2017) · Haematologica · doi:10.3324/haematol.2017.176719 · Cited by 22
Current concepts and future directions for hemato-oncologic diagnostics
Flach, J., Shumilov, E., Joncourt, R., Porret, N. A., Novak, U., Pabst, T., & Bacher, U. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102977 · Cited by 24
The genetics of myelodysplastic syndromes and the opportunities for tailored treatments
Kontandreopoulou, C., Kalopisis, K., Viniou, N., & Diamantopoulos, P. T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.989483 · Cited by 23
From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy
Ahmadi, S. E., Rahimian, E., Rahimi, S., Zarandi, B., Bahraini, M., Soleymani, M., Safdari, S. M., Shabannezhad, A., Jaafari, N., & Safa, M. (2024) · Biomarker Research · doi:10.1186/s40364-024-00676-9 · Cited by 22
Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes
Zampini, M., Riva, E., Lanino, L., Sauta, E., Reis, R. A. D., Ejarque, R. A., Maggioni, G., Termanini, A., Merlotti, A., Campagna, A., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02394 · Cited by 21
Self-citation
Attenuated Expression of Apoptosis Stimulating Protein of p53-2 (ASPP2) in Human Acute Leukemia Is Associated with Therapy Failure
Schittenhelm, M. M., Illing, B., Ahmut, F., Rasp, K. H., Blumenstock, G., Döhner, K., Lopez, C. D., & Kampa-Schittenhelm, K. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080193 · Cited by 21
Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy
Prébet, T., Cluzeau, T., Park, S., Sekeres, M. A., Germing, U., Adès, L., Platzbecker, U., Götze, K. S. S., Vey, N., Olíva, E. N., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18477 · Cited by 21
MMP9 inhibition increases erythropoiesis in RPS14-deficient del(5q) MDS models through suppression of TGF-β pathways
Youn, M., Huang, H., Cheng, C., Kam, S., Wilkes, M. C., Chae, H.-D., Sridhar, K. J., Greenberg, P. L., Glader, B. E., Narla, A., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000537 · Cited by 21
The evolving role of next generation sequencing in myelodysplastic syndromes
Spaulding, T. P., Stockton, S. S., & Savona, M. R. (2019) · British Journal of Haematology · doi:10.1111/bjh.16212 · Cited by 21
TP53 in Myelodysplastic Syndromes
Jiang, Y., Gao, S., Soubise, B., Douet‐Guilbert, N., Liu, Z., & Troadec, M. (2021) · Cancers · doi:10.3390/cancers13215392 · Cited by 22

Authors: Jädersten, M., Saft, L., Smith, A., Kulasekararaj, A., Pomplun, S., Göhring, G., Hedlund, A., Hast, R., Schlegelberger, B., Porwit, A., Hellström-Lindberg, E., & Mufti, G. J.
Affiliations: King's College London (GB)
From the Department of Medicine, Center for Experimental Hematology, and Department of Pathology and Oncology, Karolinska Institutet, Stockholm, Sweden; King's College London School of Medicine, London, United Kingdom; and Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany.
ORCID: Jädersten, Martin
Saft, Leonie
Smith, Alexander
Kulasekararaj, Austin
Göhring, Gudrun
Schlegelberger, Brigitte
Mufti, Ghulam J.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2011-05-20
Volume: 29
Issue: 15
Pages: 1971-1979
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2010.31.8576
OpenAlex: W2131256397
Cited by: 463
References: 33
Citations by year: 2026: 10 · 2025: 12 · 2024: 26 · 2023: 23 · 2022: 27 · 2021: 31 · 2020: 27 · 2019: 33 · 2018: 28 · 2017: 37 · 2016: 34 · 2015: 44 · 2014: 38 · 2013: 47 · 2012: 26
FWCI: 28.44
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Research Portal (King's College London) (submittedVersion)
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
Keywords: TP53 mutation, myelodysplastic syndrome, del(5q), p53 expression, disease progression, cytogenetic response, clone size, disease heterogeneity
MeSH terms: Adult, Aged, Aged, 80 and over, Chromosome Deletion, Chromosomes, Human, Pair 5, Female, Humans, Male, Middle Aged, Myelodysplastic Syndromes, Peptide Fragments, Prognosis, Risk, Leukemia, Myeloid, Acute, Genes, p53, Tumor Suppressor Protein p53, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks